TY - JOUR
T1 - Cardiovascular risk factors among adult patients with haemophilia
AU - Camelo, Ricardo Mesquita
AU - Caram-Deelder, Camila
AU - Duarte, Bruna Pontes
AU - de Moura, Marilia Carolina Braga
AU - Costa, Neuza Cavalcanti de Moraes
AU - Costa, Iris Maciel
AU - Roncal, Carlos Guilherme Piscoya
AU - Vanderlei, Ana Maria
AU - Guimaraes, Tania Maria Rocha
AU - Gouw, Samantha
AU - Rezende, Suely Meireles
AU - van der Bom, Johanna
N1 - Funding Information: In 2016, there were 12,119 PwH in Brazil, of whom 43% were 30 years or older []. Haemophilia treatment is publicly funded by the Brazilian National Health System. From 2006 to 2018, there was a dramatic increment in the use of FVIII and FIX concentrates, from 1.0 to 4.0 and 0.2 to 0.7 IU per capita, respectively []. Considering the improvement of haemophilia care in Brazil, life expectancy of PwH has also increased [, ]. Publisher Copyright: © 2021, Japanese Society of Hematology.
PY - 2021/6
Y1 - 2021/6
N2 - Since the introduction of episodic and prophylactic treatments with safer factor concentrates, the life expectancy of people with haemophilia (PwH) has improved considerably. Ageing-related diseases such as cardiovascular disease (CVD) have also become more prevalent in PwH. This cross-sectional study aimed to evaluate CVD risk factors and estimate 10-year risk for CVD events among PwH. Male patients ≥ 30 years were interviewed and examined. Blood tests were performed at the local laboratory. Eighty-two patients were included, of whom 83% had haemophilia A and half had severe disease. Median age at study entry was 43.0 years (interquartile range [IQR], 36.0–51.3). Prevalence of obesity, systemic arterial hypertension (SAH) and diabetes mellitus were 16%, 60% and 16%, respectively. Hypertriglyceridaemia, hypercholesterolaemia and low HDL blood levels were present in 18%, 41% and 30% of patients, respectively. Metabolic syndrome was found in 37%. The Framingham Risk Score showed that 39% of PwH had a high risk of developing cardiovascular events in the following 10 years. We conclude that, in this cohort, PwH have a higher prevalence of SAH when compared with Brazilian men without haemophilia and about two-fifths have a high risk of developing a CVD event in the following 10 years.
AB - Since the introduction of episodic and prophylactic treatments with safer factor concentrates, the life expectancy of people with haemophilia (PwH) has improved considerably. Ageing-related diseases such as cardiovascular disease (CVD) have also become more prevalent in PwH. This cross-sectional study aimed to evaluate CVD risk factors and estimate 10-year risk for CVD events among PwH. Male patients ≥ 30 years were interviewed and examined. Blood tests were performed at the local laboratory. Eighty-two patients were included, of whom 83% had haemophilia A and half had severe disease. Median age at study entry was 43.0 years (interquartile range [IQR], 36.0–51.3). Prevalence of obesity, systemic arterial hypertension (SAH) and diabetes mellitus were 16%, 60% and 16%, respectively. Hypertriglyceridaemia, hypercholesterolaemia and low HDL blood levels were present in 18%, 41% and 30% of patients, respectively. Metabolic syndrome was found in 37%. The Framingham Risk Score showed that 39% of PwH had a high risk of developing cardiovascular events in the following 10 years. We conclude that, in this cohort, PwH have a higher prevalence of SAH when compared with Brazilian men without haemophilia and about two-fifths have a high risk of developing a CVD event in the following 10 years.
KW - Cardiovascular disease
KW - Cardiovascular risk
KW - Framingham Risk Score
KW - Haemophilia
UR - http://www.scopus.com/inward/record.url?scp=85102236780&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s12185-021-03104-y
DO - https://doi.org/10.1007/s12185-021-03104-y
M3 - Article
C2 - 33677769
SN - 0925-5710
VL - 113
SP - 884
EP - 892
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 6
ER -